News

Ezogabine was not marked as an antidepressant but seemed to be an effective treatment in a small study.

Not sure what’s been recalled, withdrawn from the market, or had safety updates? Catch up on the US Food and Drug Administration’s (FDA's) recalls and safety news from this past week.

The FDA has expanded Novartis’ eltrombopag (Promacta) to include first-line treatment for adults and pediatric patients aged 2 years and older with severe aplastic anemia (SAA) in combination with standard immunosuppressive therapy (IST).

Here’s a round-up of recent designations granted by the FDA to products developed to treat rare diseases.

The antibacterial therapy has been indicated for forms of the disease driven by E. coli.

In analysis, the therapy plus standard immunosuppressive therapy resulted in a complete response rate 27% greater than that historically observed in patients treated with lone IST, over 6 months.

New results from a pair of phase 3 trials will be used to support AbbVie's anticipated NDA submission in 2019.

New research contradicts previous studies supporting the use of inositol supplementation in premature infants at risk for an eye condition that could lead to blindness.

In using the EDSS and 9HPT scales as a metric for the therapy’s influence on disability risk reduction, the investigators were additionally providing context to ocrelizumab’s benefits for ambulation rates and MS-related costs.

EMR data from the 17-18 flu season shows that cell-based influenza vaccines were more effective at preventing influenza-like illness compared to standard egg-based vaccines.

Brentuximab vedotin (ADCETRIS, Seattle Genetics) is approved in combination with chemotherapy for adults with previously untreated systemic anaplastic large cell lymphoma (sALCL) or other CD30-expressing peripheral T-cell lymphomas (PTCL), including angioimmunoblastic T-cell lymphoma and PTCL not otherwise specified.

Older age among children and the use of proton pump inhibitors are linked to severe C difficile infection in pediatric patients, according to new findings.

The influenza virus has shown resistance to a promising new drug—favipiravir—that is being developed for widespread use, including in a flu pandemic.

Research with more diverse patient populations is needed to confirm this new discovery.

In general, the high incidence and strong persistence of HPV infections among HIV-infected patients are a result of immunosuppression.

About 21% to 74% of patients with AF will also have obstructive sleep apnea. What is one medical center doing to find these patients in their cardiology department?

The investigators hope to gain FDA approval on the treatment so they can treat more patients.

A popularizing procedure among stroke centers was the basis of clinical research for the medical center, and is now improving in practice.

How many days between hospital admission and surgery could play a significant role, investigators noted.

Men who don’t get much sleep also tend to make poor sexual decisions when it comes to HIV prevention, a new study suggests.

How surgeons' duties surround the entire invasive process, and therefore make them something closer to specialists.

A meta-analysis of more than 7 million patients confirms that just 1 instance of a concussion or mild TBI is associated with a two-fold greater risk of suicide.

Strengths of the DECLARE-TIMI 58 trial included a large primary prevention population, while the nature of the study meant that adherence was likely higher than it would be in a standard setting.

Tardive dyskinesia due to lithium treatment is still rare, but the antipsyhotic therapy substitute was linked to at least 1 particular patient case.

Traditional therapy includes anti-VEGF injections into the eye. This is effective in many patients, but some remain unresponsive. Recent studies have suggested this new target.

Seizures were well controlled for up to 6 years in some patients with epilepsy receiving perampanel for partial onset seizures.

The study showed noninferiority with relation to major adverse cardiovascular events and a reduction of heart failure, though no difference in cardiovascular death compared to placebo. There appear to be renal benefits to dapagliflozin as well.

A descriptive review of 150-plus papers on drug-induced interstitial lung disease shows there is an absence of high-quality data on the disease.

Not sure what’s been recalled, withdrawn from the market, or had safety updates? Catch up on the US Food and Drug Administration’s (FDA's) recalls and safety news from this past week.

The FDA has approved revefenacin (YUPELRI) for the maintenance treatment of chronic obstructive pulmonary disease.